Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of a dexamethasone mouthwash to prevent stomatitis, a painful mouth condition, in patients receiving Datopotamab Deruxtecan Dato-DXd treatment for certain types of breast cancer or EGFR-mutated non-small cell lung cancer. This Phase IV study focuses on the incidence and severity of grade 2 or higher stomatitis within the first 12 weeks of Dato-DXd treatment. The study involves two groups one with breast cancer and the other with lung cancer, enrolling about 100 participants in total. Participants will use an alcohol-free dexamethasone mouthwash, 0.5 mg per 5 mL, four times daily by swishing 10 mL for about 2 minutes and then spitting it out without swallowing. They must avoid food or drink for at least 30 minutes after use. This mouthwash will be used throughout their standard care treatment with Dato-DXd. The study will follow participants for at least 12 weeks after starting treatment, with additional safety monitoring for about 21 months. During the study, participants will be assessed for the occurrence and severity of stomatitis, adherence to mouthwash use, and any dose changes of Dato-DXd due to stomatitis. Researchers will monitor safety and tolerability of the treatment combination through clinical evaluations, including documentation of side effects. Participants will be followed for safety up to 28 days after their last dose and may be monitored for up to 21 months to observe long-term outcomes.